Press coverage about CASI Pharmaceuticals (NASDAQ:CASI) has trended somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CASI Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.414652627404 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

A number of analysts have recently weighed in on CASI shares. ValuEngine raised CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 15th. Maxim Group restated a “buy” rating and issued a $4.00 target price on shares of CASI Pharmaceuticals in a research note on Friday, September 8th. Finally, HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of CASI Pharmaceuticals in a research note on Friday, September 8th.

CASI Pharmaceuticals (NASDAQ CASI) traded up $0.18 during midday trading on Friday, hitting $3.46. The company’s stock had a trading volume of 323,153 shares, compared to its average volume of 882,547. CASI Pharmaceuticals has a twelve month low of $0.91 and a twelve month high of $4.84.

CASI Pharmaceuticals (NASDAQ:CASI) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. equities research analysts expect that CASI Pharmaceuticals will post -0.15 earnings per share for the current fiscal year.

In related news, Director Wei-Wu He acquired 207,502 shares of CASI Pharmaceuticals stock in a transaction on Tuesday, September 19th. The stock was acquired at an average price of $1.75 per share, for a total transaction of $363,128.50. Following the purchase, the director now owns 513,525 shares of the company’s stock, valued at approximately $898,668.75. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have acquired a total of 996,329 shares of company stock valued at $1,647,138 in the last quarter. Company insiders own 24.52% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “CASI Pharmaceuticals (CASI) Receiving Somewhat Favorable Press Coverage, Study Shows” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Insider Buying and Selling by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.